Shire (SHPG) Other Long-Term Liabilities : $6,866 Mil (As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire Other Long-Term Liabilities?

Shire's other long-term liabilities for the quarter that ended in Sep. 2018 was $6,866 Mil.

Shire's quarterly other long-term liabilities declined from Mar. 2018 ($6,791 Mil) to Jun. 2018 ($6,432 Mil) but then increased from Jun. 2018 ($6,432 Mil) to Sep. 2018 ($6,866 Mil).

Shire's annual other long-term liabilities increased from Dec. 2015 ($2,993 Mil) to Dec. 2016 ($10,444 Mil) but then declined from Dec. 2016 ($10,444 Mil) to Dec. 2017 ($6,946 Mil).

Shire Other Long-Term Liabilities Historical Data

The historical data trend for Shire's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Other Long-Term Liabilities Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Other Long-Term Liabilities

Get a 7-Day Free Trial

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Shire Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Shire Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Shire's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085